US · EOLS
Evolus, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Newport Beach, CA 92660
- Website
- evolus.com
Price · as of 2024-12-31
$5.33
Market cap 278.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36.72 | +588.93% |
| Intrinsic Value(DCF) | $26.70 | +400.94% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $12.07 | ||||
| 2018 | $24.75 | ||||
| 2019 | $7.22 | ||||
| 2020 | $13.35 | $28.04 | $0.00 | $0.00 | $0.00 |
| 2021 | $10.07 | $41.04 | $0.42 | $0.00 | $0.00 |
| 2022 | $8.07 | $27.42 | $606.83 | $0.00 | $0.00 |
| 2023 | $14.07 | $37.11 | $199.87 | $0.00 | $0.00 |
| 2024 | $13.58 | $36.72 | $117.57 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Evolus, Inc.'s (EOLS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36.72
- Current price
- $5.33
- AI upside
- +588.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$26.70
+400.94% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EOLS | Evolus, Inc. | $5.33 | 278.73M | +589% | +401% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| AUTL | Autolus Therapeutics plc | $1.71 | 455.11M | +3,826% | -33% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| EHAB | Enhabit, Inc. | $13.61 | 689.9M | +90% | -75% | — | — | -2.78 | 0.82 | 0.41 | -11.59 | -2.98 | -0.99 | 48.71% | -11.12% | -15.09% | -25.81% | -9.68% | -11.58% | 1.09 | -2.68 | 1.53 | 1.41 | -6.47 | 9317.00% | -110.00% | 557.00% | 11.07% | 0.41 | 4.09% | 0.00% | 0.00% | 9.71% | -8.42 | 20.45 | 0.94 | 1.09 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| KMDA | Kamada Ltd. | $8.70 | 501.83M | +538% | -63% | -40% | -41% | 28.63 | 1.60 | 2.57 | 12.47 | 42.95 | 3.25 | 43.47% | 12.46% | 8.99% | 5.74% | 10.30% | 3.98% | 0.04 | 30.38 | 3.73 | 2.06 | -2.42 | 6667.00% | 1293.00% | -250091.00% | 8.90% | 0.96 | 18.93% | 0.00% | 0.00% | 4.96% | 17.29 | 9.41 | 2.15 | 3.15 |
| NGNE | Neurogene Inc. | $23.49 | 363.86M | — | -49% | — | — | -4.04 | 0.98 | 328.17 | -0.05 | -7.88 | 0.98 | -251.03% | -8930.27% | -8123.68% | -30.28% | -1064.50% | -26.92% | 0.04 | -6883.75 | 20.84 | 20.65 | 1.73 | 5124.00% | — | 3801.00% | -23.52% | -4.66 | -920.24% | 0.00% | 0.00% | 0.00% | -0.04 | -0.05 | 3.87 | 6.36 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| TOI | The Oncology Institute, I… | $2.89 | 284.32M | +772% | +1,754% | — | — | -1.01 | 14.97 | 0.14 | -2.36 | — | -2.91 | 13.73% | -15.28% | -16.44% | -174.89% | -70.35% | -27.75% | 34.31 | -8.02 | 2.15 | 1.88 | -1.37 | -2283.00% | 2133.00% | -2582.00% | -56.44% | -0.51 | -35.49% | 0.00% | 0.00% | 23.64% | -2.12 | -4.19 | 0.32 | 0.03 |
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- CEO
- David Moatazedi
- Employees
- 372
- Beta
- 1.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($26.70 ÷ $5.33) − 1 = +400.94% (DCF, example).